A number of studies, covering about 5000 patients, with breast cancer at different stages showed that Bcl-2 over-expression correlated to a differentiated phenotype and a favorable prognosis in patients subjected to local-regional, hormonal or cytotoxic therapies [14,27]. The gene discussed is BCL2; the disease is breast cancer.